
If a life science company includes people from outside the industry in its board, it can turn into a huge advantage – even if they don't have expert knowledge on the industry, according to business commentator Jens Christian Hansen.
He sees a clear tendency in Tuesday's announcements that Novo Nordisk has nominated Danish utility Ørsted's former President & CEO Henrik Poulsen for its company board at the same as Google's Country Director for Denmark, Malou Aamund, enters WS Audiology's board.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.